Palifosfamide Combination Therapy Shows Promising Results

The study included 22 patients and evaluated the safety and efficacy of the combination therapy.

Ziopharm Oncology's intravenous Zymafos (palifosfamide or ZIO-201) has received promising clinical results in an ongoing Phase Ib open-label dose escalation study in patients with small cell lung cancer, and other selected cancers, when administered with etoposide and carboplatin.

The study included 22 patients and evaluated the safety and efficacy of the combination therapy. If found that the maximum tolerated dose of palifosfamide was 130 mg/m² when administered in combination with etoposide and carboplatin.

Of the 22 patients, 13 are evaluable for efficacy. Five patients have partial responses, four have stable disease, and four have progressive disease.

Palifosfamide, a DNA